-
Mashup Score: 0Empagliflozin Cuts Risk of Cardiovascular Death, More Severe CKD by 28%, Study Finds - 2 year(s) ago
Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, reduced the risk of death or worsening progression of chronic kidney disease (CKD) by 28%, according to results published Friday at Kidney Week 2022.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 0Impact of Empagliflozin on Left Ventricular Strain: Insights From the EMPA-HEART CardioLink-6 Randomized Clinical Trial - 2 year(s) ago
1. Zelniker T.A., Wiviott S.D., Raz I., et al. “SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials”. Lancet 2019;393:31-39. 2. Verma S., Mazer C.D., Yan A.T., et al. “Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and…
Source: JACC: Cardiovascular ImagingCategories: Expert Picks, Latest HeadlinesTweet-
In this data from the EMPA-HEART RCT, in #T2DM with #cvCAD, treatment with the #SGLT2i empagliflozin was not associated with changes in #EchoFirst LV strain. https://t.co/dvTX7dfTwO #JACCIMG #Empagliflozin #cvImaging #CardioTwitter https://t.co/0sXkm4DcJj
-
-
Mashup Score: 0Empagliflozin restores neutropenia and neutrophil dysfunction in a young patient with severe congenital neutropenia type 4 - 2 year(s) ago
Article InfoPublication HistoryAccepted: October 11, 2022Received in revised form: October 8, 2022Received: April 12, 2022Publication stageIn Press Journal Pre-ProofFootnotesConflicts of interest: The authors declare that they have no relevant conflicts of interest.Clinical ImplicationPatients with severe congenital…
Categories: Allergy-Immunology, Latest HeadlinesTweet-
In Press! #Empagliflozin restores #neutropenia and #neutrophil #dysfunction in a #young #patient with #severe #congenital #neutropenia #type4 https://t.co/RjbRGwKpth
-
-
Mashup Score: 0
AbstractAims. Effective and safe decongestion remains a major goal for optimal management of patients with acute heart failure (AHF). The effects of the sodium–
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
What's the impact of empagliflozin on decongestion in acute heart failure? New insights from the EMPULSE trial in EHJ! https://t.co/O1MZTFPWCc #SGLT2 #decongestion #heartfailure #empagliflozin #cardiotwitter @escardio @ESC_Journals https://t.co/QLJYNgl1Zo
-
-
Mashup Score: 6
AbstractAims. Effective and safe decongestion remains a major goal for optimal management of patients with acute heart failure (AHF). The effects of the sodium–
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
Impact of empagliflozin on #decongestion in Acute #HeartFailure : the #EMPULSE trial Initiation of #empagliflozin in patients hospitalized for #AHF results in early, effective and sustained decongestion which is associated with clinical benefit at day 90 https://t.co/C4Nq06BWTb https://t.co/MpmTAIVKgw
-
-
Mashup Score: 2
Source Citation Filippatos G, Butler J, Farmakis D, et al. Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes. Circulation. 2022;146:676-86. 35762322
Source: Annals of Internal MedicineCategories: Cardiologists, Latest HeadlinesTweet-
Synthesis of #diabetes subanalysis of #EmperorPreserved RCT in @AnnalsofIM w @FudimMarat In #HFpEF, #empagliflozin improved primary outcome regardless of #DM, though event rates & ARR - plus renal benefits - were ⬆️ in pts w DM https://t.co/eQ79vuRI2A https://t.co/9UKLYW5VVT https://t.co/U7qUdxsFeJ
-
-
Mashup Score: 69Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction - 2 year(s) ago
BACKGROUND: Women and men with heart failure (HF) and preserved ejection fraction may differ in their clinical characteristics and their response to therapy. The aim of this study was to evaluate the
Source: CirculationCategories: Cardiac Surgery, Latest HeadlinesTweet-
#OriginalResearch: In EMPEROR-Preserved #empagliflozin reduced cardiovascular outcomes & improved health status to a similar degree in both women and men with #HFpEF, irrespect... @javedbutler1 @Filippatos @JJheart_doc @Bocchi @unic_cardiovasc #AHAJournals https://t.co/My1VdUANpz https://t.co/IUMCJYwDHl
-
-
Mashup Score: 1Chronic Heart Failure Therapies and Developing Treatments in Individuals With Recent Myocardial Infarction - 2 year(s) ago
This narrative review discusses trials evaluating the use of existing chronic heart failure therapies in individuals with recent myocardial infarction and the development of new treatments targeting this population.
Source: jamanetwork.comCategories: Cardiologists, Latest HeadlinesTweet-
Trials in process testing #SGLT2i in individuals with #heartattack with #heartfailure include: DAPA-MI EMPACT-MI EMMY trial #dapagliflozin #empagliflozin A review @JAMACardio https://t.co/n8fs2dkSRE
-
-
Mashup Score: 1Empagliflozin in acute Myocardial Infarction: the EMMY trial - 2 year(s) ago
AbstractBACKGROUND AND AIMS. Sodium–glucose co-transporter 2 inhibition reduces the risk of hospitalisation for heart failure and for death in patients with sym
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
#Empagliflozin in #AMI: the #EMMY trial Empagliflozin initiated shortly after an AMI improves #NTproBNP, as well as structural and functional #EchoFirst parameters ( LVEF, E/e’, LVESV and LVEDV) without significant safety concerns https://t.co/hQ5jz3uOCH @escardio #HeartFailure https://t.co/BFsXhFZxT3
-
-
Mashup Score: 5SGLT-2 inhibition by empagliflozin has no effect on experimental arterial thrombosis in a murine model of low-grade inflammation - 2 year(s) ago
AbstractAims. Low-grade inflammation couples dysmetabolic states to insulin resistance and atherosclerotic cardiovascular (CV) disease (ASCVD). Selective sodium
Source: OUP AcademicCategories: Cardiology News and Journals, Latest HeadlinesTweet-
New #CardiovascularResearch study shows #SGLT2 inhibition by #empagliflozin has no effect on experimental #arterial #thrombosis in a model of low-grade #inflammation https://t.co/BFeneTQDwL @CVR_TomaszGuzik @glenpyle @DrMikeDrozd #SGLT2inhib #CardioTwitter #ESCCongress https://t.co/Nq7NWO4XJf
-
#Empagliflozin Cuts Risk of Cardiovascular Death, More Severe #CKD by 28%, Study Finds. #kidneydisease #kidneywk https://t.co/SDIDokTAuU https://t.co/U0EayTXkpa